Literature DB >> 7015026

Current problems in the diagnosis and management of chronic active hepatitis.

A J Czaja.   

Abstract

Although corticosteroids have been shown to be effective in the treatment of most forms of severe chronic active hepatitis, many problems remain in the diagnosis and management of patients with this disease. Difficulties in determining chronicity, establishing the correct diagnosis, and deciding when and how to initiate and stop therapy jeopardize successful management. Mechanisms of drug action, pharmacokinetics, long-term sequelae of therapy, and optimum treatment schedules have been incompletely described. A satisfactory program of management remains undefined for patients with less than severe disease, hepatitis B surface antigenemia, and suboptimal results after conventional treatment. The goals of this review are to identify problem areas and to indicate directions for future investigation and improvement.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7015026

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

Review 1.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

2.  Chronic hepatitis. Aetiology and current management.

Authors:  W G Cooksley; R A Bradbear; J W Halliday; L W Powell
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

Review 3.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

4.  Duration of chronic active hepatitis and the development of cirrhosis.

Authors:  A Vegnente; V F Larcher; A P Mowat; B Portmann; R Williams
Journal:  Arch Dis Child       Date:  1984-04       Impact factor: 3.791

5.  Multisystemic disease with intracranial hypertension and autoimmune cytopenia in chronic active hepatitis.

Authors:  M Girino; A Riccardi; M Danova; C M Montecucco; G Ucci; E Ascari
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.